Cyplasin Biomedical Ltd. Announces Second U.S. Patent for Cyplasin
EDMONTON, Nov. 2 /CNW/ - Cyplasin Biomedical Ltd today announced that its
U.S. Patent application Nr 10/501,098 entitled "Cytotoxic Cyplasin of the Sea
Hare, Aplysia punctata, cDNA Cloning and Expression of Bioreactive
Recombinants" has been granted as US patent Number US 7,271,242 B2. The patent
claims cover the production of a cytotoxic protein by mammalian cells and its
use to treat cancer.